about
Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients.[American Society of Clinical Oncology (ASCO) 2012 essential data: the editorial board of the Bulletin du Cancer point of view].Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).Phase II trial of paclitaxel-epirubicin in patients with recurrent soft-tissue sarcoma.Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).[Renal involvement in cancer and renal paraneoplastic syndromes].[Plasma cell leukemia].Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC.Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie CelluStage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.[American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view].Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.[Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].The off-label use of targeted therapies in sarcomas: the OUTC'S programCould enteral nutrition improve the outcome of patients with haematological malignancies undergoing allogeneic haematopoietic stem cell transplantation? A study protocol for a randomized controlled trial (the NEPHA study).Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).Severe aplastic anemia associated with eosinophilic fasciitis: report of 4 cases and review of the literature.Proteasome inhibition: a new approach for the treatment of malignancies.Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors.Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS.Possible benefits of curcumin regimen in combination with taxane chemotherapy for hormone-refractory prostate cancer treatment.Biological markers in haematological malignancies.Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.Prevalence of malnutrition in adult patients previously treated with allogeneic hematopoietic stem-cell transplantation.Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics.Enteral versus parenteral nutritional support in allogeneic haematopoietic stem-cell transplantation.A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD.Impact of ATG Dose on the Outcome of Patients Undergoing Reduced Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies.Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.[Bisphosphonate and denosumab-related osteonecrosis of the jaw: Epidemiology, diagnosis and management].Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie CelTCL1 expression patterns in Waldenström macroglobulinemia.Large granular lymphocytic leukemia associated with Lambert-Eaton Myasthenic Syndrome: A case report.Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen for elderly patients (60 years and older) with hematologic malignancies using unrelated donors: a retrospective study from the French society for stem ceLung postmortem autopsy revealing extramedullary involvement in multiple myeloma causing acute respiratory distress syndrome.
P50
Q30356737-411EE7A0-5272-4AB5-A9FF-F8E94D61550EQ30585579-F9290A8B-C5E6-419C-AE49-B31385406F21Q31018689-D5AC66FE-1AB3-4C99-A59F-A02FB1B37109Q33276494-35C64F68-4D50-4EFA-8AFB-CE981C35BC47Q33345633-91892BCC-7874-424A-8D2C-3623210F2557Q33370331-1FAA7919-2EBC-425C-81F4-B6EC8EEDC961Q33381250-7382D586-9007-4B2C-8CE0-880B34FAB30EQ33382803-D21C798F-B644-43AD-8165-8B158620A14EQ33393151-672D104D-1193-4853-9462-2989B4987895Q33398613-6254E2FB-056D-476C-BEBB-49BDD9AC7147Q33418815-FBC9F796-9C19-44A6-8190-275C9732F033Q33420170-5E2E227B-0644-4CF0-AAA8-FC1E64D37397Q33886185-62AF95EE-AE37-41DE-8FEC-F77B07B14580Q34044905-AA3B870C-A352-441F-BF69-7D57C89D830AQ34106002-D195B2CE-46BF-4CB9-AE87-84793536BF06Q34583699-E85E0EE0-708A-46A9-AA8C-289F62366F8FQ34586436-C580FF2F-F4E3-4C12-B43D-578EA5F825B2Q34662863-5CC78F1E-680E-4656-9A55-DB5B1C4113BCQ34897996-2168A976-089B-4E16-9105-96B9B6E089B9Q35337571-16646099-4190-4AAB-BDDE-D4F3C488379FQ35776264-9D97A7E1-B4F2-474A-836F-2E6D64780432Q36009002-14FEDE1C-E108-46BF-B0C1-BBC0D457B271Q36326490-7DE7B3F9-6BC1-47AD-B137-C3D70683E22AQ37132720-3A6B4A7E-05FF-43F5-845E-1D767EA1DD18Q37429911-EF689D5E-D1F0-4701-8335-C3E399241AF5Q37680771-0F20B190-64FC-487C-AB9B-A2962E0C8E2CQ38223321-A221BC24-3859-4D50-AEB0-1F58213AED4BQ38372551-8086C7D0-8441-42D0-A07C-95FEC3678563Q38846420-182C015A-8096-44DF-AD28-E8FF6552D6EBQ39483197-F53DAB6E-F708-41E0-A4E1-18548CCF5B58Q40238223-087B33A8-DEEC-4759-AD28-694A1170EC1DQ40430861-3EABC92F-B80E-44F1-8E38-FA24BE956175Q40541937-D4F5F0BC-5A9F-435B-AE5A-FFCA4B71EB94Q40690432-D74CE3C1-D6AD-47E0-8A4E-3C13E9C186F1Q41096935-95BC6065-06CF-43DA-B6DC-CA90C8FD5FC9Q41155250-680AEAAE-02C5-4127-B588-F41C343E33D0Q41192923-20285CDA-5EF9-496D-A295-85AADFD6FC4CQ41868211-455ED5DC-C686-49C4-94C4-36F2DB1C8107Q42397451-0218CC45-8E15-4F67-BA4F-ED8DE3DF1A3AQ42825628-D5DC1CC9-E34A-415F-AA0F-35CF888F0439
P50
name
Jacques-Olivier Bay
@en
Jacques-Olivier Bay
@nl
type
label
Jacques-Olivier Bay
@en
Jacques-Olivier Bay
@nl
prefLabel
Jacques-Olivier Bay
@en
Jacques-Olivier Bay
@nl